Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer
- 1 January 2008
- journal article
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 22 (1) , 98-104
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Cytokines in breast cancerCytokine & Growth Factor Reviews, 2006
- Significance of interleukin-6 (IL-6) in breast cancer (review)Breast Cancer Research and Treatment, 2006
- Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancerCancer Letters, 2006
- Chronic Inflammation and Breast Pathology: A Theoretical ModelBiological Research For Nursing, 2005
- The Effects of Standard Anthracycline-Based Chemotherapy on Soluble ICAM-1 and Vascular Endothelial Growth Factor Levels in Breast CancerClinical Cancer Research, 2004
- Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapyCytokine, 2004
- Cardiovascular Complications of Cancer TherapyCirculation, 2004
- The increased expression of adhesion molecules ICAM‐3, E‐ and P‐selectins on breast cancer endotheliumThe Journal of Pathology, 1995
- Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survivalEuropean Journal of Surgical Oncology, 1995
- The Significance of Soluble lnterleukin-2, Soluble Interleuk in-2 Receptors, Soluble ICAM-1 and β2-Microglobulin in Breast Cancer PatientsTumor Biology, 1995